Get the Stockscreener App
1.89
3.08%
-0.06
After Hours:
1.86
-0.03
-1.59%
Neumora Therapeutics Inc stock is traded at $1.89, with a volume of 1.02M.
It is down -3.08% in the last 24 hours and up +15.95% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$1.95
Open:
$1.95
24h Volume:
1.02M
Relative Volume:
1.03
Market Cap:
$306.08M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-0.7457
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
+3.28%
1M Performance:
+15.95%
6M Performance:
+163.75%
1Y Performance:
-87.73%
1-Day Range:
$1.82
$1.98
1-Week Range:
$1.80
$2.02
52-Week Range:
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.89 | 315.79M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-02-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-10-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-07-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-25 | Downgrade | Stifel | Buy → Hold |
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
Using data models to predict Neumora Therapeutics Inc. stock movement2025 Dividend Review & Real-Time Volume Analysis Alerts - newser.com
Will Neumora Therapeutics Inc. see short term momentum2025 Valuation Update & Fast Moving Stock Trade Plans - newser.com
Neumora Therapeutics' (NMRA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Tools to monitor Neumora Therapeutics Inc. recovery probabilityJobs Report & Community Verified Watchlist Alerts - newser.com
Published on: 2025-10-09 06:47:56 - newser.com
Will Neumora Therapeutics Inc. stock attract more institutional investorsQuarterly Market Summary & Free High Return Stock Watch Alerts - newser.com
Visual analytics tools that track Neumora Therapeutics Inc. performanceTrade Entry Report & High Accuracy Trade Alerts - newser.com
Is Neumora Therapeutics Inc a good long term investmentVolume Weighted Average Price & Rapid Wealth Building Tips - earlytimes.in
Will breakout in Neumora Therapeutics Inc. lead to full recoveryWeekly Profit Report & AI Forecast Swing Trade Picks - newser.com
What insider trading reveals about Neumora Therapeutics Inc. stockQuarterly Market Summary & Stepwise Swing Trade Plans - newser.com
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Neumora Therapeutics Inc. recovery potential after sell offTrade Volume Report & Weekly Return Optimization Alerts - newser.com
Forecasting Neumora Therapeutics Inc. price range with options dataJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
Is Neumora Therapeutics Inc. trending in predictive chart modelsGap Down & Risk Adjusted Buy and Sell Alerts - newser.com
Neumora Therapeutics to Host Virtual R&D Day Highlighting Innovative Therapeutics Pipeline on October 27, 2025 - Quiver Quantitative
Neumora Therapeutics to Host Virtual R&D Day on October 27 - Yahoo Finance
What analysts say about Neumora Therapeutics Inc stockMarket Sentiment Surveys & Start Your Free Trading Journey Today - earlytimes.in
What drives Neumora Therapeutics Inc stock priceEx-Dividend Date Alerts & Minimal Capital Growth Plans - earlytimes.in
Neumora Therapeutics Inc Stock Analysis and ForecastFederal Reserve Announcements & Free Proven Portfolio Growth Strategies - earlytimes.in
Neumora Therapeutics appoints Paul Berns as CEO - MSN
J.P. Morgan Downgrades Neumora Therapeutics(NMRA.US) to Sell Rating - 富途牛牛
Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating - MSN
Following a 85% Decline Over Last Year, Recent Gains May Please Neumora Therapeutics, Inc. (NASDAQ:NMRA) Institutional Owners - 富途牛牛
3 Promising Penny Stocks With Market Caps At Least $100M - simplywall.st
Aug Reactions: Is Neumora Therapeutics Inc benefiting from innovation trendsLong Setup & Weekly Momentum Stock Picks - خودرو بانک
Neumora Therapeutics (NASDAQ:NMRA) Downgraded by JPMorgan Chase & Co. to Underweight - MarketBeat
Market Pulse: Is Neumora Therapeutics Inc. a stock for growth or value investorsTrade Entry Report & Technical Confirmation Alerts - خودرو بانک
Guidance Update: How liquid is Neumora Therapeutics Inc. stockTrade Signal Summary & Stock Market Timing Techniques - خودرو بانک
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neumora Therapeutics Inc Stock (NMRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
13,871 |
23,468 |
7,405,004 |
| Milligan Michael Lee | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
1,978 |
3,351 |
22,470 |
| Aurora Daljit Singh | Chief Strategy Officer |
Feb 18 '25 |
Sale |
1.68 |
8,565 |
14,347 |
88,935 |
| Lenz Robert A. | Head of R&D |
Feb 18 '25 |
Sale |
1.67 |
5,614 |
9,383 |
309,092 |
| Pinto Joshua | President |
Feb 18 '25 |
Sale |
1.67 |
8,048 |
13,477 |
76,952 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):